BeyondSpring Reports Widened Q1 Loss and Critical Cash Runway
BYSI is trading near its 52-week low of $1.21 (15% above the low) on light trading volume (0.3× avg).
Summary
BeyondSpring Inc. reported a substantial increase in its net loss for Q1 2026 and a critically low cash position, raising concerns about its short-term financial viability despite positive updates on its drug pipeline.
Key Events · Earnings and Guidance · BYSI
-
Significant Net Loss Increase
The company reported a total net loss of $6.67 million for Q1 2026, a substantial increase from a net income of $1.17 million in Q1 2025.
-
Critical Cash Runway
Cash, cash equivalents, and short-term investments stood at $7.9 million as of March 31, 2026. With an estimated quarterly cash burn of $4.7 million, the company has approximately 1.7 quarters of cash runway.
-
Positive Plinabulin Preclinical Data
New preclinical data presented at AACR 2026 demonstrated Plinabulin's ability to enhance both efficacy and tolerability in ADC-based regimens, positioning it as a potential backbone agent.
-
Molecular Glue Degrader Enters Phase 1
SEED Therapeutics, a partially divested subsidiary, advanced its novel RBM39 molecular glue degrader (ST-01156) into Phase 1 clinical development, with initial data showing complete tumor eradication in a neuroblastoma model.
Analysis · BYSI · Life Sciences
BeyondSpring Inc. reported a significant increase in its total net loss for Q1 2026, swinging from a net income of $1.17 million in the prior year to a net loss of $6.67 million. This financial deterioration, coupled with a cash position of $7.9 million and an estimated quarterly cash burn of $4.7 million, indicates a very short cash runway of approximately 1.7 quarters. While the company announced positive preclinical data for Plinabulin and the advancement of ST-01156 into Phase 1, these pipeline developments are overshadowed by the immediate and severe financial challenges.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 990 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BYSI was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.2M. The 52-week trading range was $1.21 to $3.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.